About Orthocell

Orthocell’s origins lay in a purposeful meeting of bright, solutions-focused minds more than 15 years ago, who saw the potential for biological solutions to repair the human body, in applications traditionally dominated by materials like metal and plastic.

One of those leaders was Orthocell’s Co-Founder and Managing Director, Paul Anderson, a former orthopedic nurse who moved swiftly into the commercial side of medicine to work in product sales and ultimately, as a successful entrepreneur, working alongside respected academic visionaries in the orthopedics space.

Through his association with The University of Western Australia, Paul started collaborating with Orthocell’s now Co-Founder and Chief Scientific Officer, Professor Ming Hao Zheng, to develop technologies to produce novel regenerative medicine treatments.

Theirs is a strong and proven partnership. Paul and Professor Zheng have previously commercialized cartilage repair technology together – and sold it to an American company – which had a current market capitalization of more than US $1B. Key learnings from this chapter challenged them to pursue the next ‘big thing’ in regenerative medicine.

With two promising products in the pipeline, they secured venture capital funding from a Western Australian-based VC firm to build the laboratory and fund the clinical trial programs; together with non-diluted funding from the State government. Orthocell was listed on the Australian Securities Exchange (ASX) in 2014.g new applications for both existing and future products.

More than 70,000 patients have been treated with Orthocell products to date, with no adverse events reported, as of March 2025.

The clinical utility of every Orthocell product is underpinned by the Company’s mission to improve mobility, function and quality of life – without exception.

Orthocell works with leading surgeons and centres of excellence to translate research into novel products that improve the standard of care for patients with a variety of musculoskeletal injuries.

Orthocell’s success stems from a deep understanding of tissue engineering principles, and in particular the interaction between cells and scaffolds. Orthocell products enhance the body’s natural ability to heal and promote regeneration of nerve, tendon, cartilage and dental bone defects.

Our products are carefully designed to assist surgeons – in particular, orthopedic, plastic, reconstructive and dental surgeons – to simplify procedures, save operative time and deliver consistent and predictable outcomes for their patients.

The Orthocell team is committed to expanding its suite of medical devices and is exploring new applications for both existing and future products.